Natural compounds targeting mitochondrial dysfunction: emerging therapeutics for target organ damage in hypertension

Xiaolin Liao, Yuanshan Han, Ying He, Jianjun Liu, Yuhong WangFrontiers in Pharmacology 2023 · DOI

Abstract

Hypertension generally causes target organ damage (TOD) in the heart, brain, kidney, and blood vessels. This can result in atherosclerosis, plaque formation, cardiovascular and cerebrovascular events, and renal failure. Recent studies have indicated that mitochondrial dysfunction is crucial in hypertensive target organ damage. Consequently, mitochondria-targeted therapies attract increasing attention. Natural compounds are valuable resources for drug discovery and development. Many studies have demonstrated that natural compounds can ameliorate mitochondrial dysfunction in hypertensive target organ damage. This review examines the contribution of mitochondrial dysfunction to the development of target organ damage in hypertension. Moreover, it summarizes therapeutic strategies based on natural compounds that target mitochondrial dysfunction, which may be beneficial for preventing and treating hypertensive target organ damage.

Introduction

While current pharmacological interventions effectively lower blood pressure, hypertension remains a primary global cause of mortality due to its progressive damage to "target organs," including the heart, kidneys, brain, and vasculature. Recent research suggests that hypertension-induced target organ damage (TOD) is fundamentally a disease of mitochondrial failure. In hypertensive states, mitochondria—the cellular powerhouses—do not merely lose efficiency; they become pathological drivers of disease by leaking reactive oxygen species (ROS), undergoing uncontrolled fragmentation, and triggering premature apoptosis.

This review synthesizes nearly two decades of research to explore how natural compounds—ranging from common flavonoids to rare alkaloids—can rescue mitochondrial health and prevent organ failure. By targeting the cellular roots of TOD, these compounds offer a promising therapeutic window beyond traditional blood pressure management.

Mechanisms of Mitochondrial Dysfunction in Hypertension

The pathology of hypertensive TOD can be categorized into four primary mitochondrial "failure modes":

  1. Impaired Dynamics: An imbalance between fission (splitting) and fusion (merging), often driven by the overactivation of the fission protein DRP1.
  2. Bioenergetic Failure: Dysfunctional electron transport chains (ETC) leading to reduced ATP production.
  3. Oxidative Stress: Excessive production of mitochondrial ROS (mtROS), which damages cellular components.
  4. Mitophagy and Apoptosis: The failure to clear damaged mitochondria or the inappropriate triggering of programmed cell death.

Therapeutic Potential of Natural Compounds

Natural compounds provide a vast library of low-toxicity molecules capable of addressing these failure modes. Unlike synthetic drugs that often target single receptors, many natural phenolics and flavonoids exhibit "poly-pharmacology," simultaneously reducing ROS, boosting biogenesis, and inhibiting cell death pathways.

Summary of Flavonoids and Phenolics targeting mitochondrial dysfunction in hypertension.

Key examples include:

  • Acacetin (ACT): Promotes mitochondrial dynamics and inhibits apoptosis in vascular and cardiac tissues via the PI3K/AKT pathway.
  • Resveratrol (RSV): Enhances mitochondrial biogenesis through the SIRT1 and PGC-1α pathways, offering protection to the heart and kidneys.
  • Epigallocatechin-3-gallate (EGCG): Protects the brain by regulating the Bax/Bcl-2 ratio to prevent neuronal apoptosis.
Summary of Phenolics, Alkaloids, Terpenoids, and other compounds targeting mitochondrial dysfunction.

Further therapeutic agents include Curcumin (CCM), which improves endothelial function and reduces oxidative stress in the brain, and Astaxanthin (ATX), which inhibits mitochondrial fragmentation in vascular cells.

Discussion: Regulatory Hubs and Organ Specificity

A recurring theme in mitochondrial rescue is the role of SIRT3, a primary mitochondrial deacetylase. Compounds like Baicalein and Dihydromyricetin upregulate SIRT3, which activates antioxidant enzymes like SOD2 and "reboots" mitochondrial health.

Furthermore, different organs exhibit specific vulnerabilities:

  • Heart: High energy demands make it susceptible to bioenergetic failure, leading to hypertrophy.
  • Vessels: Mitochondrial ROS drive the "phenotypic switching" of smooth muscle cells, resulting in vessel stiffening.
  • Kidney: Hypoxia-induced mitochondrial failure in renal tubules accelerates chronic kidney disease.

Conclusion and Future Perspectives

Natural compounds represent a promising frontier for "mitochondrial resuscitation" in hypertension. However, several challenges remain for clinical translation. Most evidence currently relies on animal models, such as Spontaneously Hypertensive Rats (SHRs), and cell cultures. Additionally, many compounds like Curcumin and Resveratrol suffer from poor oral bioavailability, requiring advanced delivery systems like nano-formulations. Future research must prioritize clinical validation and the optimization of pharmacokinetics to bridge the gap from bench to bedside.

Summary updated

Abstract

Hypertension generally causes target organ damage (TOD) in the heart, brain, kidney, and blood vessels. This can result in atherosclerosis, plaque formation, cardiovascular and cerebrovascular events, and renal failure. Recent studies have indicated that mitochondrial dysfunction is crucial in hypertensive target organ damage. Consequently, mitochondria-targeted therapies attract increasing attention. Natural compounds are valuable resources for drug discovery and development. Many studies have demonstrated that natural compounds can ameliorate mitochondrial dysfunction in hypertensive target organ damage. This review examines the contribution of mitochondrial dysfunction to the development of target organ damage in hypertension. Moreover, it summarizes therapeutic strategies based on natural compounds that target mitochondrial dysfunction, which may be beneficial for preventing and treating hypertensive target organ damage.
BibTeX
@inproceedings{liao2023natural,
  author = {Xiaolin Liao and Yuanshan Han and Ying He and Jianjun Liu and Yuhong Wang},
  title = {{Natural compounds targeting mitochondrial dysfunction: emerging therapeutics for target organ damage in hypertension}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.1209890},
}
Figure